Four drug programs face FDA PDUFA decisions in mid-to-late 2026: Ifinatamab Deruxtecan, Ziihera, Tecentriq, and Gedatolisib. Each decision is binary — approval re-rates the program and sector peers; rejection reverses it.
Ifinatamab Deruxtecan and Ziihera represent the ADC (antibody-drug conjugate) cohort in this queue. Tecentriq brings checkpoint inhibitor exposure. Gedatolisib adds a small molecule PI3K/mTOR inhibitor to the calendar. Together they create an overlapping risk window unusual even by oncology biotech standards.
Supporting the combination-approach rationale, AbbVie presented CLL durability data at EHA 2026: venetoclax plus obinutuzumab showed a median time to next treatment of approximately eight years versus chemoimmunotherapy.1 That sustained remission benchmark strengthens the clinical logic behind ADC combinations now awaiting FDA review.
Three next-generation modalities are building a 2027 pipeline floor beneath the near-term PDUFA cluster. Century Therapeutics presented preclinical data for CNTY-813 — an iPSC-derived allogeneic cell therapy for type 1 diabetes — at ADA 2026.2 T1D affects approximately nine million people worldwide. Current islet transplantation achieves insulin independence in roughly 70% of patients at one year but requires chronic systemic immunosuppression.2 CNTY-813's design incorporates immune evasion mechanisms to address that gap.
Epcoritamab, a CD3xCD20 bispecific antibody, is advancing in follicular lymphoma. Selinexor, an exportin-1 inhibitor, is being evaluated in the SENTRY trial. Both push the sector's catalyst horizon into 2027.
The ASCEND proof-of-concept readout is expected in Q1 2027, alongside CR-001 ADC combination data — providing a second-wave catalyst leg for investors positioned ahead of near-term decisions.
ADC approvals historically trigger re-rating of related programs across the sector. A single rejection rarely collapses the full thesis — but sequencing and positioning across PDUFA dates determines whether investors capture the upside or absorb the drawdown. With four decisions and multiple pivotal trial readouts clustered over 18 months, the 2026–2027 oncology calendar offers no quiet quarter. Every date is a standalone bet with asymmetric outcomes.
